Directorate Change

Directorate Change

Eco Animal Health Group Plc

22 December 2014

Eco Animal Health Group plc (the "Company")

Appointment of director

The Board of Eco Animal Health Group plc is pleased to announce the appointment of Mr Anthony Paul Rawlinson, aged 57, as a Non-Executive Director of the Company with effect from 1 January 2015.

Mr Rawlinson is a chartered accountant with over 25 years corporate finance experience advising smaller quoted companies. After spending 14 years at Henry Ansbacher & Co and Strand Partners, he founded Dowgate Capital Advisers in 2001 and led its growth and development. He was also Chairman of its AIM quoted parent company, Dowgate Capital, which was sold to a competitor in a recommended transaction in 2009. Mr Rawlinson co-founded Cairn Financial Advisers LLP, a firm of AIM Market corporate advisers in 2010.

Peter Lawrence, Executive Chairman, commented;

"The Directors are delighted to welcome Tony to the Board. We have known Tony for several years and his individual knowledge and skills will complement us and be a great asset to the company as we continue to grow the business."

Save as disclosed below there are no other details required to be disclosed under paragraph (g) of

Schedule 2 of the AIM Rules for companies.

Mr Rawlinson has the following current partnerships and directorships:

Cairn Financial Advisers LLP
Cairn Financial Holdings Limited
Camura Limited

Former directorships held in the last 5 years:

Terrain Energy Limited
City Financial Associates Limited
Ellis Stockbrokers Limited
Dowgate Capital Advisers Limited

Other information required under paragraph (g) of Schedule 2 of the AIM Rules for companies:

Mr Rawlinson was a director of Colorvision plc when it went into receivership in 1996.

Contacts:

ECO Animal Health Group plc	Â	Â
Peter Lawrence			020 8336 6190
Â
Spiro Financial
Anthony Spiro			020 8336 6196

Â

Peel Hunt LLP (Nominated Adviser) Dan Webster, Richard Brown, George Sellar   020 7418 8900

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.